Cargando…
Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
Pemigatinib is a potent inhibitor of fibroblast growth factor receptor being developed for oncology indications. It is primarily metabolized by cytochrome P450 (CYP) 3A4, and the ratio of estimated concentration over concentration required for 50% inhibition ratio for pemigatinib as an inhibitor of...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286713/ https://www.ncbi.nlm.nih.gov/pubmed/35506332 http://dx.doi.org/10.1002/psp4.12805 |